LI Qin , TAO Ye
  • Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China;
TAO Ye, Email: liqinhx@163.com
Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective　 We searched for evidence on mycophenolate mofetil(MMF) as a treatment for patients with diffuse proliferative lupus nephritis.
Methods　 We attempted to find the current best evidence by searching The Cochrane Library(Issue 4, 2005), MEDLINE(1990 to June 2007), CMB(1980 to December 2006), CNKI(1979 to October 2007). We critically appraised the available evidence.
Results　 Four systematic reviews and 6 randomized controlled trials of high quality were available. MMF and prednisolone were found to be an effective continuous induction-maintenance treatment for diffuse proliferative lupus nephritis. MMF was associated with less drug toxicity.
Conclusion　 Given the current evidence and our clinical experience, and considering the patient and the values and preferences of his family,MMF was given at 1 g daily in combination with steroids at the beginning. No obvious adverse effects occurred during 3 months of follow-up.

Citation： LI Qin,TAO Ye. Evidenced-Based Therapy of Lupus Nephritis with Mycophenolate Mofetil. Chinese Journal of Evidence-Based Medicine, 2007, 07(12): 904-906. doi: Copy